Last reviewed · How we verify

rosiglitazone maleate/metformin hydrochloride

GlaxoSmithKline · FDA-approved active Small molecule

rosiglitazone maleate/metformin hydrochloride is a Thiazolidinedione/Biguanide combination Small molecule drug developed by GlaxoSmithKline. It is currently FDA-approved for Type 2 diabetes mellitus.

This combination drug improves blood sugar control by increasing insulin sensitivity through a thiazolidinedione and reducing hepatic glucose production through a biguanide.

This combination drug improves blood sugar control by increasing insulin sensitivity through a thiazolidinedione and reducing hepatic glucose production through a biguanide. Used for Type 2 diabetes mellitus.

At a glance

Generic namerosiglitazone maleate/metformin hydrochloride
SponsorGlaxoSmithKline
Drug classThiazolidinedione/Biguanide combination
TargetPPAR-γ (rosiglitazone); Complex I of mitochondrial respiratory chain (metformin)
ModalitySmall molecule
Therapeutic areaDiabetes
PhaseFDA-approved

Mechanism of action

Rosiglitazone is a thiazolidinedione that activates peroxisome proliferator-activated receptor gamma (PPAR-γ), enhancing insulin sensitivity in muscle and adipose tissue. Metformin is a biguanide that decreases hepatic glucose production and improves peripheral glucose uptake. Together, they provide complementary mechanisms to reduce hyperglycemia in type 2 diabetes.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about rosiglitazone maleate/metformin hydrochloride

What is rosiglitazone maleate/metformin hydrochloride?

rosiglitazone maleate/metformin hydrochloride is a Thiazolidinedione/Biguanide combination drug developed by GlaxoSmithKline, indicated for Type 2 diabetes mellitus.

How does rosiglitazone maleate/metformin hydrochloride work?

This combination drug improves blood sugar control by increasing insulin sensitivity through a thiazolidinedione and reducing hepatic glucose production through a biguanide.

What is rosiglitazone maleate/metformin hydrochloride used for?

rosiglitazone maleate/metformin hydrochloride is indicated for Type 2 diabetes mellitus.

Who makes rosiglitazone maleate/metformin hydrochloride?

rosiglitazone maleate/metformin hydrochloride is developed and marketed by GlaxoSmithKline (see full GlaxoSmithKline pipeline at /company/gsk).

What drug class is rosiglitazone maleate/metformin hydrochloride in?

rosiglitazone maleate/metformin hydrochloride belongs to the Thiazolidinedione/Biguanide combination class. See all Thiazolidinedione/Biguanide combination drugs at /class/thiazolidinedione-biguanide-combination.

What development phase is rosiglitazone maleate/metformin hydrochloride in?

rosiglitazone maleate/metformin hydrochloride is FDA-approved (marketed).

What are the side effects of rosiglitazone maleate/metformin hydrochloride?

Common side effects of rosiglitazone maleate/metformin hydrochloride include Weight gain, Fluid retention/edema, Hypoglycemia, Gastrointestinal disturbances (nausea, diarrhea), Headache, Upper respiratory tract infection.

What does rosiglitazone maleate/metformin hydrochloride target?

rosiglitazone maleate/metformin hydrochloride targets PPAR-γ (rosiglitazone); Complex I of mitochondrial respiratory chain (metformin) and is a Thiazolidinedione/Biguanide combination.

Related